Iron deficiency by Beguin, Yves & Estatiev, R.
42 
lower the serum EPO value. Hence serum EPO lev-
els are the result of a balance between the rate of 
EPO production and its utilization by the ery-
throid marrow. 
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2.2. Iron deficiency 
Iron deficiency is the mûst important pathophy-
siologital mechanism leading to anemia in IBD. It 
occurs in over one third of the patients suffering 
from Crohn's ,disease or u1cerative colitis (1). Iron 
metabolism is an active research field and recent 
advances have been made in understanding patho-
physiological processes involved in the regulation 
of iron homeostasis. 
2.2.1. Physiology of iron mètabolism 
Il Iron absorption 
Iron is an essential element for mast organisms 
from prokaryotes to mammals, being a part of nu-
merous enzymes participating in redox reactions 
or oxygen delivery (2-4). The major source of iron 
is food, where it cornes in the form ofheme-bound 
or non-heme iron. Iron absorption occurs only in 
the duodenum and upper jejunum. Heme-bound 
iron has a considerably higher bioavailability than 
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non-herne iro~. Herne, released proteolyticall 
from myoglobm and hemoglobin (mostly fro~ 
meat), bmds to the herne carrIer protein BCP-l 
and enters the mucosa epithelium unchanged via 
endocytosis, where iron is subsequently freed from 
the complex by the low pH; however, this process 
has not yet been studied in detail. 
More is known about the absorption of non-heme 
iron. Most iron is available in the fonn of ferric 
(Fe3+) ions, which do not readilypass the mucosal 
barrier; therefore a reduction to ferrous ions (Fé+) 
is needed to facilitate transport. Reducing agents 
are present in the food itself, the most common ex-
ample being vitamin C. An adclitional mechanism 
utilizes the membrane-bound ferrireductase 
DcytB (duodenal cytochrome B). Ferrous iron 
then passes through the brush-border membrane 
via the divalent metal transporter DMT -l, which 
operates via a proton electrochemical gradient (2, 
4-6). 
Several factors influence iron uptake in the gut 
mucosa, among them the form of iron and its re-
dox state in the food, the pH in the intestinal lu-
men, the presence of chelating agents in the food 
(e.g. phytic acid, oxalic acid) and the expression 
levels ofDMT-1 in the epithelial ceils. As a conse-
quence, only a small percentage of the ingested 
iron (physiologieaily 1-2 mg per day) is absorbed 
(6). 
Once iron has entered the ceU, it is either used for 
metabolic purposes,' incorporated into the iron 
storage protein ferritin, or is released into the cir-
culation for the needs of the organism. The exact 
pathway by whieh iron crosses the gut epithelial 
ceil from the apical brush border to the basolateral 
sicle has not been clarified sufficiently. Both tran-
scytosis as weil as a participation of iron chaperone 
proteins have been suggested to play a role in this c-i._·~ 
process (7, 8). Once iron reaches the basolateral 
surface, it leaves the enterocyte via ferroportin and 
is packed iuto the iron transport protein tranS- -
ferrin ta enter the circulation. Prior to bînding ta 
transferrin, the ceruloplasmin - related copper-
containing membrane-bound ferroxidase he-
phaestin oxidises Fé+ back to Fe3+ (6) (summa-
rized in Figure 2.3). 
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Figure 2.3: Seheme ofiron absorption. Herne absorp-
tion is mediated by Hep1 (heme carrier protein 1) and 
ferrous iron is released after degradation of herne by 
heme oxygenase.Afterreduction to its ferrous state by 
the ferrireductase Dcytb, non-heme iron is imported 
into enteroeytes by DMTl (dimetal transporter 1 or 
Nramp2). Within enteroeytes, iron can either be stored 
in ferritin (later excreted through cel1 exfoliation) or 
enter the so-called labile iron pool From where itcan be 
activeJy exported by ferroportin or Ireg1. Hephaestin 
then oxidizes ferrous iron back to ferric iron, a!lowing 
its binding to circu!ating Tf. 
2.2.2. Iron distribution and utilization 
AImost all iron released into the circulation by the 
enterocytes is transferrin-bound, a transport form 
that can be utilized by ail ceil types including the 
developing red blood ceils that have the highest 
iron demand of ail ceil types (2, 4, 5, 8). One mole-
cule of transferrin (Tf) can carry two ferrie ions. 
Apotransferrin, mono- and diferrie transferrÎn are 
ail found in the blood plasma, where the distribu-
tion of iron betvi'een these forms relates to the 
transferrin saturation. Tf enters the cells via endo-
cytosis mediated by the ubiquitously expressed 
transferrin receptor l (TfR1) and iron is subse-
quently released from the binding by the low pH. 
HFE, a surface protein with homology to MHC 
class 1 molecules that physicallyassociates with ~2-
microglobulin, can interfere with this process by 
binding to TiR! (3). The C282Y mutation, wruch is 
typical of genetic hemochromatosis in most cases, 
hampers the ability of HFE to interact with ~2M, 
with the consequences ofHFE degradation and re-
d~ced ceIl surface expression. HFE expression is 
hlghest in hepatocytes but it is alsa present in 
Kupffer cells and enterocytes. As their binding sites 
On TfR1 overlap, competition ofHFE With diferric 
transferrin has been suspected. However, the role 
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ofHFE in the regulation of iron absorption is not 
clear. 
A truncated soluble form of the TiRI (sTiR!) cir-
culates in the plasma and its concentration is di-
rectly proportional to the total body mass of cellu-
lar TiRI (9). Itis therefore largelyinfluenced bythe 
level of erythropoietic activity (through changes in 
the number of erythroblasts) and to a lesser extent 
by iron stores (through reguJation of the number 
ofTfRl per ceIl). sTfRl is an excellent indicator of 
iron deficient erythropoiesis, particularly for the 
differential diagnosis of iron deficiency (increased 
sTfRl and low ferritin) versus inflammation (nor-
mal sTfRl and ferritin) or for detecting iron defi-
ciencyin a patientwith concomitant inflammation 
(increased sTfRl and normal ferritin). However, it 
cannot be used as a marker of iron deficiency in 
erythropoietic disorders or du"ring EPO treatment. 
An alternative transferrin receptor, TfR2, is ex-
pressed only on hepatocytes, duodenal crypt cells 
and erythroid ceils (8). Unlike TiR!, it is believed 
to have a primarily regulative function, as descri-
bed below. 
Within mast celis, iron stores are built up in the 
form of ferritin (10), which represents a molecular 
"nanocage" built up by24 subunits offerritinheavy 
and light chains and holding up to 4,500 ferric ions. 
Serum ferritin is secreted in proportion to storage 
iron in macrophages and hepatocytes and its levels 
thus represent a quantitative marker ofiron stores. 
It is a highly specifie marker, any decreased value 
demonstrating exhaustion ofiron stores. 1tis how-
ever not very sensitive, because numerous condi-
tions are associated with falsely elevated serum 
ferritin levels. These inc1ude hepatic cytolysis, in-
flammation, renal failure, hyperthyroidism, poor-
ly controlled diabetes mellitus, sorne tumors and 
the rare hyperferritin-cataract syndrome. lndeed 
cutoff values for iron deficiency can be as high as 
40-120 ~g/l instead of the classicall2 ~g/l in situa-
tions such as renaI failure or inflammation. 
The human body contains 30-40 mg/kg of iron, 
adding up to approximately 4 g in adults (Il). Iron 
is mostly contained in hemoglobin (2.5 g), ferritin 
(1 g) and other heme and non-heme proteins 
(0.5 g), while plasma iron amounts to only 3 mg. 
Iron lasses are limited to about 1 mg/day through 
gastro-intestinal and skin desquamation. A nor-






but only a smail fraction) 1 mg in a male adult, is 
absorbed. Iron requirements depend on age 
(1.5 mg/day during puberty), sex (1.5 mg in wo-
men because of menstruallosses) and pregnancy 
(3.5 mg/ day and even 5 mg/day in 3,d trimester). 
65 % of the total iron content is localized in the 
erythrocytes. Erythropoiesis is 'a highly dynamic 
process WÎth 2xlOll new red blood cells produced 
each day to maintain a constant erythrocyte count 
(4,5). The average lifetime of an erythrocyte is 120 
days. This means that the daily amount of ab-
sorbed iron is not sufficient ta Cover the needs of 
erythropoiesis thus making iron recycling neces-
sary. Senescent erythrocytes undergo phagocytosis 
by cells of the monocyte-macrophage system 
(MMS) mainly in the spleen and liver. In the pha-
gosomes) the heme complexes are degraded, and 
iron exits in the form of ferrous ions via a different 
isoform of DMT -1 to be stored in the form of 
ferritin or be released back in the circulation via 
ferroportin. In this case) the copper containing 
protein ceruloplasmin acts as the principal plasma 
ferroxidase to convert Fe2+ to Fe3+ prior to trans-
ferrin binding. 
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Figure 2.4: Iron distribution in the organism. The av-
erage iron content of the organs as weil as the daily 
flow of iron through the different compartments are 
shawn. For detailed description, see text. Modified 
Irom Cell 2004 (8). 
The liver is the most important iron storage organ. 
VVhen systemic iron is in excess, it is taken up by 
the hepatocytes and the MMS cells and is stored in 
the farm of ferritin for future use. As soon as the 
body iron levels drop, iron is released by the he-
patocytes via the ferroportin/ceruloplasmin sys-
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-tem. In this way the liver is capable ofbalancing al-
terations in plasma iron concentration (4) (n$" Fi-
gure 2.4). 
2.2.3. Regulation of iron homeostasis 
AImost all iron used by the cells is recycled. The 
daily Iron losses through shedding of epithe!ial 
cells and bleeding from minor injuries account for 
only 1-2 mg, and the same amount is taken up ta 
main tain a body iron balance. Since no excretion 
mechanism is present) iron homeostasis ls regu-
lated on the level of absorption and release from 
the macrophage and hepatocytic iron storages (5) 
7,8). 
2.2.3.1. Regulation by hepcidin 
Hepcidin is the recently characterized major regu-
lator ofsystemic iron homeostasis (2) 4, 7, 12, 13). 
This smali molecule (25 aminoacids) be!ongs to a 
family of anti-microbial peptides (e.g. defensin) 
and is synthesized in the liver. It interferes WÎth the 
iron efflux into the plasma from enterocytes, ma-
crophages and hepatocytes by binding to ferro-
portin and causingits internalization and degrada-
tian. Hepcidin Levels rise w1.1en the body iron levels 
are high) thus inhibiting iron absorption and re-
lease in a negative feedback manner. Conversely, 
under conditions of iron deficiency) the plasma 
hepcidin concentration is low, which leads to a 
higher iron uptake by the enterocytes and efflux 
from macrophages and the hepatic storage. 
Furthermore) hepcidin synthesis is enhanced dur-
ing inflammation, mostlyunder the control ofIL-6 
and IL-l. This leads to a redistribution ofiron with 
iron being trapped in macrophages and hepato-
cytes, whereas plasma levels, mirrored by the 
transferrin saturation, drop. This physiological de-
fence mechanism depletes microorganisms from 
iron that is needed for their growth and also con-
tributes to the development of anemia of chronic 
disease, which is discussed in the foilowing chap-
ter. It lS aiso knovvn that hypoxia (via the hypoxia 
inducible factor-l, HIF-l) the levels of which are 
high in anemia) as well as enhanced erythropoiesis 
(rather than anemia per se) diminish hepcidin pro-
duction (8, 12, 13) (w Figure 2.5). The erythro-
poietic regulator is stronger than the iron regulator 
but its nature remains elusive, as the potentially 
good candidate sTfRI (9) has been excluded. 
2.2. Iron deficiency 
Internalization and degradation 







----- Figure 2.5: Regulation of the systemic iron homeostasis by hepcidin. High body iron !eve!s an~ i.nflammation 
trigger hepatic hepcidin production, whereas hypoxia and increased iron demand keep hepçldm lev:ls low. 
Hepcidin in hi bits iron efflux via internaJization of ferroportin in enterocytes and macro~~ages thus lea~lng to a 
decrease in dietary iron absorption and utilization of recycled iron from the MMS. Modlfled from Semnn G, IBO 
_ 2006, Nemeth E, Science 2004, Vaulont, S. J Clin lnvest 2005. 
The exact pathway of activation ofhepcidin is not 
known. The aIready discussed protein HFE as weil 
as transferrin receptor 2 (TfR2), a homolog of the 
ubiquitously expressed TiRl that may act as an 
iron sensor and is mutated -in certain hernochro-
matosis forms, seem to act as non-essential up-
stream activators ofhepcidin expression, whereas 
hemojuvelin (HjV), which plays a role in the devel-
apment of the severe juvenile hemochromatosis, 
acts further downstream and is absolutelyessentiaI 
for hepcidinsynthesis. HN acts as a bone morpho-
genic protein (BMP) coreceptor and its signaling 
pathway has been partiaIly discovered, but it is not 
known how HFE and TfR2 regulate hepcidin ex-
pression (7). Diferric transferrin could induce the 
signal transduction pathway to increase hepcidin 
expression by (1) outcompeting HFE for TfRl 
binding, resulting in large numbers of unbound 
surface HFE molecules, and (2) stabilizing TfR2. 
Another possibility consists in placing the iron 
senSOr in Kupffer ceIls that aiso express HFE and 
could elaborate a paracrine factor regulating hep-
cidin expression in hepatocytes. 
2.2.3.2. Regulation of the expression of 
iron related genes 
Iron can directly regulate the expression levels of 
proteins invofved in iron rnetabolism via the so 
called iron responsive elernents (IREs) (8). These 
are stern-loop sequences in the rnRNAs that are 
recognized by the iron regulatory proteins (IRPI 
and IRP2). The IRPs bind to these structures under 
conditions of iron deficiency. The effect of this 
binding is dependent on the localization of the 
IREs. When the IRE is situated in the 5' -untrans-
lated region (UTR), iron deficiency leads to an in-
hibition of translation. This is the case mth the 
heavy and light ferritin chains, ferroportin and 
sorne proteins of iron utilization such as 5-arnino-
laevulinic add synthetase, participating in the 
herne synthesis, or mitochondrial aconitase. On 
the contrary, when IREs are localizeâ in the 3'-
UTR, IRP-binding leads to protein up-regulation 
due to increased mRNA stability. Such regulation 
has been described for Tf1U and the œil mern-
brane-bound isoform ofDMT-l. 
Other non-IRE-re1ated regulatory rnechanisrns 
also influence gene expression of iron-re1ated 
genes. Such mechanisms act on transcriptional as 
welI as on translationallevel. Cytokines such as IL-
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6, IL-l, IFN-y and TNF-a. stimulate H-ferritin 
rnRNA transcription but inhibit the expression of 
TfRI. Toll-like receptor 4 signalling downregulates 
the mRNA-sythesis of ferroportin. INF-y also 
blocks ceruloplasmin translation (8). 
2.2.4. Pathophysiology of iron defi-
ciency 
Iron deficiency occurs when iron 1055 exceeds the 
amount of iTon absorbed by the gut. A situation of 
a negativê iron balance is present when not enough 
iTon is ingested, when iTOU absorption is inhibited, 
when the body demand of iron is elevated (e.g. 
during pregnancy or puberty), or because of iron 
loss through bleeding. Bleeding from the genito-
Ufinary tract in females or from the gastrointesti-
naI tract in both sexes is the leading cause of iron 
deficiency. 
Anemia in inflammatory bowel disease is mainly 
contributed to iron deficiency (1,14,15). Several 
of the described pathogenetic mechanisms play a 
role in the development of an iron deficit in IBD. 
Patients with IBD, especiallywomen, have a lower 
daily iron intake, mainly non-herne iron, predo-
minantly due to avoidance of liigh fibre Fe-rich 
and -fortified foods (16), which may exacerbate 
abdominal symptoms. Poor iron absorption due 
to structural changes in the mucosa is expected 
only in the relatively rare upper gastrointestinal 
form of Crohn's disease (L4 according to the Vi-
enna classi~cation), although iron malabsorption 
has been described in up to 90 % of the pediatrie 
IBD-patients. An additional factor affecting the 
absorption of dietary iron is the increased level of 
hepcidin (as a result of chronic inflammation), 
leading to a diminished iron efflux from entero-
cytes. However, the main cause for negative iron 
balance in IBD remains chranic blood 10S5 through 
the ulcerated intestinal rnucosa (1,14) .. 
A shortage of extracellular iron leads to a decrease 
in apoferritin synthesis and subs~quently to a fall 
of serum ferritin concentration. This drop in depot 
iron is the first sign of iron deficiency (1lY" Table 
2.1). In the initial stages of iron deficiency, the 
transferrin saturation may be within the normal 
range, al).d erythropoiesis mayfunction weil. How-
ever, if the negative iron balance persists, the trans-
ferrin saturation becomes lower (deficiency in 
transport iron), and the body iron reserves are no 
longer sufficient to sustain a normal hemoglobin 
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synthesis. The consequence is the development of a 
hypochromic microcytic anemia. The full-blovvn 
picture of iron deficiency presents with a decrease 
of plasma ferritin, decrease in transferrin satura:' 
tion, a compensatory rise in apotransferrin, an 
over-expression of transferrin receptor l and its 
soluble counterpart (sTfRl). However, iron defi-
cient erythropoiesis may occur even if iron stores 
are not exhausted or are even elevated. This is 
called functional iron deficiency that OCCurs when 
macrophage iron mobilization is not sufficient to 
match iron needs in the bone marrow. This can be 
encountered ifiron needs are increased when rnar-
row erythroid activity is stimulated (e.g. by Epo 
therapy) or if iron release by macrophages is im-
paired (e.g. in the anemia of chronic disease) (tra" 
Table 2.1). 
• Stage 1 : Iron' depletion 
· . - Ferritirr <30 fig/l 
Stage 2 : Iron deficient erythropoiesis 
- Serum iron <60 Ilg/dl 
:- Transferrin saturation <20 0/0 
'- Hypocruomic RBC >5.% 
• Reticulocyte hemoglobin content (CHr) 
<28pg 
~ Soluble transferrÎn receptor- >7 mg!l 
- Erythrocyte protoporphyrin >70 ~g/dl 
• Stage 3 : Iron detlciency anemia 
- Hemoglobin <12g/dl (femàle) or <13 g/dl 
(male) 
- Hematocrit <36 % (female) or <39 % 
(male) 
- RBC number normal, later decreased 
- MCV <SO fi (microcytosis) 
- MCH <28pg (hypochromia) 
• Functional iron deficiency 
R Same as above for ferritin >30 
Table 2.1: Laboratory findings in iron deficiency. 
A differentpathogenetic mechanism that maycon~ 
tribute to the scarcity ofiron for the erythropoiesis 
in IBD relates to a disorder ofiron distribution due 
to high concentrations of pro-inflammatory cyto~ 
kines. The latter induce expression of hepcidin, 
which, as we already described, inhibits iron re-
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monocyte-macrophage system and hepatocytes) 
leading to high plasma ferritin but low transferrin 
saturation. Again, T:fRl and also sTfRl may be up-
regulated as a sign of insufficient erythropoiesis 
caused by iron deficiency. The constellation of 
high iron depots (indicated byplasma ferritin) and 
lowtransportiron (indicated bytransferrin satura-
tion) is the mast characteristic feature of anemiain 
chranîe disease, which will be discussed in the fol-
rowing chapter. 
Iron deficiency is the leading cause of anemia in 
IBD. A negative iron balance is mainly contri-
buted to bleeding from the ulcerated gut rnu-
cosa, although insufficient nutritional ITon up-
take, absorption deficit as weIl as inhibited iTon 
release from the storage compartments due to 
hepcidin action also contribute to the patho-
genesis of iron deficiency. Recent advances in 
the research of iron homeostasis improve our 
understanding of the processes leading ta the 
development of anemia in IBD. 
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2.3. Anemia of chronic Clisease 
Anemia of chronic disease (ACD) is the most fre-
quent anemia in hospitalized patients) and after 
iron deficient anernia (IDA) the second most fre-
quent anemia in the world. ACD occurs in patients 
with chronic diseases involving acute or chronic 
immune activation (l, 2).ACD isthus found in pa-
tients suffering from severe acute and chronic in-
fections) malignancies and auto-immune disor-
ders including IBD. The prevalence of anemia in 
the latter condition was estimated between 20-
60 % (.3). The prevalence and severity of anemia is 
positively associated with an advanced stage of the 
underlying disease. 
2.3.1. Pathophysiology 
ACD is an immune-driven condition in which 
cytokines and acute phase proteins alter body iron 
homeostasis, erythroid progenitor ceIl prolifera-
tion, erythropoietin production and red ceil life 
span. 
Iron retention within celIs of the reticuloendo-
thelial system (RES) leads to limitation of iron 
availabilityfor erythroid progenitor cells) and thus 
to an iron -restricted erythropoiesis. This can be re-
ferred ta an increased iron acquisition by cells of 
the RES) such as macrophages, while at the same 
time iron re-distribution from macrophages is re-
duced (<& Figure 2.6). Macrophages have multiple 
